- Home
- CHPT vs UNCY Comparison
CHPT vs UNCY Comparison
Compare CHPT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | UNCY |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 145.3M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHPT | UNCY |
|---|---|---|
| Price | $6.27 | $7.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $9.25 | ★ $25.67 |
| AVG Volume (30 Days) | 478.0K | ★ 514.7K |
| Earning Date | 06-03-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | $675,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $16.63 | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $0.47 |
| 52 Week High | $12.62 | $8.34 |
Technical Indicators
Market Signals| Indicator | CHPT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 61.97 |
| Support Level | $5.60 | $5.95 |
| Resistance Level | $6.73 | N/A |
| Average True Range (ATR) | 0.33 | 0.41 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 18.11 | 66.46 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.